You are viewing: South Korea Oral Proteins & Peptides Market analysis

The South Korea Oral Proteins & Peptides Market was valued at $65.8 Million in 2025 and projected to reach to $135 Million by 2030, representing a compound annual growth rate of 15.5%. South Korea's oral proteins and peptides market is poised for substantial expansion through 2030, driven by demographic shifts, rising healthcare expenditure, and increasing prevalence of chronic diseases.

South Korea Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Oral Proteins & Peptides Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 15.5%, reflecting strong demand for innovative oral delivery solutions in South Korea's advanced healthcare ecosystem.
  • The market expansion is driven by South Korea's aging population, rising prevalence of chronic diseases, and increasing consumer preference for non-invasive therapeutic options. South Korea's pharmaceutical and biotechnology sectors are investing heavily in oral protein and peptide formulations, supported by robust regulatory frameworks and significant R&D capabilities.
  • The country's healthcare infrastructure and high healthcare spending per capita position South Korea as a key market for next-generation oral therapeutics.
  • Between 2025 and 2030, South Korea is expected to see accelerated adoption of oral peptide-based treatments across diabetes management, gastrointestinal disorders, and metabolic conditions, driven by both domestic innovation and international partnerships..

Key Market Statistics

  • CAGR (2025-2030) 15.5% CAGR
  • Market Size, 2025 ~USD 65.8 Million
  • Forecast, 2030 ~USD 135 Million
  • Country South Korea

South Korea Oral Proteins & Peptides Market Overview

Aging Population Catalyst :

South Korea's rapidly aging demographic, with over 17% of the population aged 65+, is driving significant demand for oral proteins and peptides as therapeutic solutions for age-related conditions and nutritional deficiencies.

Advanced Healthcare Infrastructure :

South Korea's world-class healthcare system and high pharmaceutical R&D investment create an ideal environment for adoption of innovative oral delivery technologies and bioavailable peptide formulations.

Strong Market Valuation Growth :

The market is projected to more than double from USD 65.8 million in 2025 to USD 135.0 million by 2030, representing a robust 15.5% CAGR, outpacing many developed markets in Asia-Pacific.

Biotech Innovation Hub :

South Korea's thriving biotechnology sector and government support for life sciences innovation position the country as a key market for next-generation oral protein and peptide therapeutics.

South Korea Oral Proteins & Peptides Market Dynamics

  • The country's sophisticated healthcare infrastructure and strong biotech ecosystem support rapid adoption of advanced oral delivery formulations.
  • Consumer awareness of preventive healthcare and nutritional supplementation continues to grow, particularly among affluent, health-conscious demographics.
  • South Korea's regulatory environment, while stringent, facilitates faster market entry for innovative therapies compared to Western markets.
  • Strategic partnerships between domestic pharmaceutical companies and international biotech firms are accelerating product development and commercialization.
  • The market will likely see increased competition from both established players and emerging startups, driving innovation in bioavailability enhancement and patient compliance solutions..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • South Korea's oral proteins & peptides market will double from $65.8M (2025) to $135M (2030), growing at 15.5% CAGR.
    • South Korea's advanced healthcare infrastructure and high R&D investment position it as a regional leader in oral peptide therapeutics.
    • Aging demographics and chronic disease prevalence in South Korea are primary drivers of market expansion through 2030.
    • South Korea's regulatory environment and biotech ecosystem support rapid commercialization of innovative oral protein delivery technologies.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    South Korea Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical Companies : South Korean and international pharma firms need market-specific data to evaluate market entry opportunities, assess competitive positioning, and develop localized oral protein and peptide product portfolios for this growing market.
    • Biotech & Life Sciences Firms : Biotech companies focused on oral delivery innovations require detailed South Korea market insights to identify licensing opportunities, partnership prospects, and commercialization pathways in this advanced biotech hub.
    • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in South Korea's healthcare sector need comprehensive market data to assess growth potential, identify acquisition targets, and make informed capital allocation decisions.
    • Medical Device & Nutraceutical Manufacturers : Companies in adjacent sectors need South Korea-specific market intelligence to understand demand drivers, regulatory requirements, and distribution channels for oral protein and peptide products in this premium healthcare market.
    • Healthcare Consultants & Analysts : Consulting firms and research analysts require granular South Korea market data to support client advisory work, competitive benchmarking, and strategic recommendations in the oral therapeutics space.

    Key Companies in the South Korea Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for South Korea's oral proteins and peptides market with verified 15.5% CAGR projections through 2030, enabling accurate financial forecasting and investment decisions specific to this high-growth market.
    • Competitive Landscape Intelligence : Gain detailed insights into South Korean market dynamics, key players, and competitive positioning to identify partnership opportunities, market entry strategies, and differentiation tactics in this advanced healthcare ecosystem.
    • Demographic & Regulatory Insights : Understand South Korea's unique aging population trends, healthcare policies, and regulatory pathways that influence market adoption, enabling tailored product development and go-to-market strategies for this specific market.
    • Investment & Expansion Planning : Access comprehensive market data to support investment decisions, facility planning, and resource allocation for companies seeking to establish or expand operations in South Korea's high-potential oral therapeutics sector.
    • Strategic Forecasting Through 2030 : Leverage detailed South Korea-specific projections and trend analysis to anticipate market shifts, emerging opportunities, and potential challenges, enabling proactive strategic planning and competitive advantage.

    Frequently asked questions

    What is the current market size of oral proteins and peptides in South Korea?

    South Korea's oral proteins and peptides market was valued at USD 65.8 million in 2025, with strong growth anticipated through the forecast period.

    What is the projected market size for South Korea by 2030?

    South Korea's oral proteins and peptides market is forecast to reach USD 135.0 million by 2030, representing a 15.5% CAGR from 2025.

    What factors are driving growth in South Korea's oral proteins market?

    South Korea's market growth is driven by an aging population, rising chronic disease prevalence, advanced healthcare infrastructure, and strong biotech R&D capabilities.

    How does South Korea's market compare to global trends?

    South Korea's 15.5% CAGR is competitive within the Asia Pacific region, supported by the country's high healthcare spending and innovation-focused regulatory environment.

    Which therapeutic areas are most promising in South Korea?

    South Korea shows strong potential in diabetes management, gastrointestinal disorders, and metabolic conditions, where oral peptide therapies offer significant clinical advantages.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status